Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer

被引：4
|
作者：
Chiramel, Jaseela [1 ]
Tay, Rebecca [1 ]
Califano, Raffaele [1 ,2 ,3 ]
机构：
[1] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[2] Manchester Univ Hosp NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[3] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
PHASE-III; CONSOLIDATION CHEMOTHERAPY; RADIOTHERAPY; CONCURRENT; CISPLATIN; RADIATION; PEMBROLIZUMAB; ETOPOSIDE; TRIAL;
D O I：
10.21037/jtd.2018.04.29
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S991 / S994
页数：4
相关论文
共 50 条
  • [21] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [22] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    [J]. JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [23] Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC)
    Jokhadze, N.
    Kiladze, I.
    Katselashvili, L.
    Kacharava, M.
    Jankarashvili, N.
    Zumbadze, I.
    Kalandarishvili, N.
    Melkadze, T.
    Gogua, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S66 - S67
  • [24] Concurrent chemo-radiotherapy in non-small cell lung cancer: preliminary clinical outcomes
    Karakaya, E.
    Franks, K. N.
    Snee, M.
    Clarke, K.
    Turner, R.
    Stuart, R.
    Murray, L. J.
    [J]. LUNG CANCER, 2013, 79 : S63 - S63
  • [25] Efficacy of Chemo-Radiotherapy (CRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression
    Adam, Julien
    Boros, Angela
    Lacas, Benjamin
    Lacroix, Ludovic
    Pignon, Jean-Pierre
    Caramella, Caroline
    Planchard, David
    Levy, Antonin
    Besse, Benjamin
    Le Pechoux, Cecile
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S244 - S244
  • [26] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [27] Consolidation Chemotherapy following Concurrent Chemo-radiotherapy has a Trend of Improving Survival in Patients with Stage III Non-small Cell Lung Cancer
    Tang, Y.
    Cao, J.
    Li, J.
    Zhang, X.
    Wang, L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S514 - S515
  • [28] Comparison of effectiveness between chemotherapy alone versus chemo-radiotherapy in stage III non-small cell lung cancer: A phase II study
    Stathopoulos, GP
    Malamos, NA
    Antonadou, D
    Throuvalas, NA
    Thalassinos, N
    Zoitopoulos, M
    [J]. ONCOLOGY REPORTS, 1997, 4 (01) : 119 - 122
  • [29] Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT)
    Adam, J.
    Boros, A.
    Lacas, B.
    Lacroix, L.
    Pignon, J. P.
    Caramella, C.
    Planchard, D.
    Levy, A.
    Besse, B.
    Le Pechoux, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S604 - S604
  • [30] The role of radiotherapy in stage III non-small cell lung cancer
    Jassem, J.
    [J]. LUNG CANCER, 2006, 52 : S4 - S5
12345